BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15062366)

  • 1. Iodine 131 ((131)I) as adjuvant therapy of differentiated thyroid cancer.
    Lamonica D
    Surg Oncol Clin N Am; 2004 Jan; 13(1):129-49. PubMed ID: 15062366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Radioiodine therapy and radioiodine after-care in differentiated thyroid gland carcinomas].
    Börner AR; Müller-Gärtner HW
    Zentralbl Chir; 1997; 122(4):274-85. PubMed ID: 9221638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer.
    Handkiewicz-Junak D; Wloch J; Roskosz J; Krajewska J; Kropinska A; Pomorski L; Kukulska A; Prokurat A; Wygoda Z; Jarzab B
    J Nucl Med; 2007 Jun; 48(6):879-88. PubMed ID: 17536106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
    Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
    Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.
    Azrif M; Slevin NJ; Sykes AJ; Swindell R; Yap BK
    Radiother Oncol; 2008 Oct; 89(1):105-13. PubMed ID: 18579244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer.
    Shaha AR
    Laryngoscope; 2004 Mar; 114(3):393-402. PubMed ID: 15091208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
    Lind P; Igerc I; Kohlfürst S
    Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment for microcarcinoma of the thyroid--clinical experience.
    Küçük NO; Tari P; Tokmak E; Aras G
    Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of external beam radiotherapy in the management of differentiated thyroid cancer.
    Mazzarotto R; Cesaro MG; Lora O; Rubello D; Casara D; Sotti G
    Biomed Pharmacother; 2000 Jul; 54(6):345-9. PubMed ID: 10989971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years.
    Brierley J; Tsang R; Panzarella T; Bana N
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):418-27. PubMed ID: 16181234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioiodine as an adjuvant therapy and its role in follow-up of differentiated thyroid cancer.
    Padma S; Sundaram PS
    J Cancer Res Ther; 2016; 12(3):1109-1113. PubMed ID: 28054519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the diagnosis and therapy of distant metastases of differentiated thyroid carcinoma.
    Zanotti-Fregonara P; Hindié E; Faugeron I; Moretti JL; Ravasi L; Rubello D; Toubert ME
    Minerva Endocrinol; 2008 Dec; 33(4):313-27. PubMed ID: 18923368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management and outcome of recurrent well-differentiated thyroid carcinoma.
    Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of 131I in the treatment of well differentiated thyroid cancer.
    Woodrum DT; Gauger PG
    J Surg Oncol; 2005 Mar; 89(3):114-21. PubMed ID: 15719384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic thyroid cancer unresponsive to conventional therapies: novel management approaches through translational clinical research.
    Sarlis NJ
    Curr Drug Targets Immune Endocr Metabol Disord; 2001 Aug; 1(2):103-15. PubMed ID: 12476792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined radioiodine (I131) treatment and radio-guided surgery for recurrent cervical well-differentiated thyroid cancer].
    Schachter P; Shimonov M; Lorberboim M
    Harefuah; 2005 Mar; 144(3):168-72, 232, 231. PubMed ID: 15844454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma.
    Pitoia F; Tamer EE; Schere DB; Passerieu M; Bruno OD; Niepomniszcze H
    Medicina (B Aires); 2006; 66(2):125-30. PubMed ID: 16715760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.